Bio-Matrix Scientific Group And Therinject LLC Begin Development Of Tumor Banking Facility In Conjunction With Cancer Therapeutic Vaccine

Main Category: Cancer / Oncology
Also Included In: Immune System / Vaccines
Article Date: 25 Sep 2009 - 0:00 PDT

email to a friend   printer friendly   opinions  

Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) announced today that the Company and Therinject LLC have begun development of a tumor banking facility. Tumor banking will allow storage and ease of sourcing for tumor cells to be utilized in cancer vaccines.

Therinject's Chief Scientific Officer, Steven Josephs, Ph.D. said, "I believe tumor banking potentially provides a major resource for future cancer research. It will allow researchers to quickly access specimens and cells from a variety of tumors, facilitating the development of antigens for immuno-therapies."

A spokesperson for the Company noted that tumor banking dovetails into the areas of immuno-therapeutic vaccines currently being pursued by both the Company and the Company's majority owned subsidiary, Entest BioMedical, Inc. (OTCBB: ENTB).

Both the Company and Entest BioMedical, Inc. are working with Therinject to develop immuno-therapeutic cancer treatments initially intended for veterinary applications while gathering data in support of human clinical trials.

Bio-Matrix Chairman & CEO David Koos stated, "Cancer is the #1 cause of death among dogs. It's estimated that 1 out of every 3 dogs will get cancer. There are estimated to be approximately 74.8 million owned dogs in the United States and 39% of US households have at least one dog."

As previously noted by the Company, it expects once their immuno-therapeutic cancer vaccine is in the hands of veterinarians it should generate 6,000 treatment cases in the first year at $3,000 per case. The tumor bank is a major factor in facilitating this revenue.

Source
Bio-Matrix Scientific Group

• Additional
• References
• Citations